CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

@inproceedings{Gregory2015CDK9IB,
  title={CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo},
  author={Gareth Peter Gregory and Simon J. Hogg and Lev Kats and Eva Vidacs and Adele J Baker and Omer Gilan and Marcus Lefebure and Benjamin P. Martin and Mark A Dawson and Ricky W. Johnstone and Jake Shortt},
  booktitle={Leukemia},
  year={2015}
}
can thus conclude that the junction region of the IgH rearrangement in MM is stable and can be used as a target for MRD assessment by ASO RQ-PCR and more, also by deep-sequencing methods, as it constantly identifies the myeloma cells responsible for relapse. In conclusion, our results show that, in the dominant myeloma clone, the CDR3 region of IGH remains constant across all the stages of disease evolution. This major clone signature is not modified by clinical or biological changes in the… CONTINUE READING
19 Extracted Citations
16 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 19 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 16 references

In vivo ef fi cacy of the Bcl - 2 antagonist ABT - 737 against aggressive Myc - driven lympho

  • KD Mason, CJ Vandenberg, CL Scott, AH Wei, S Cory, Huang DCS
  • Proc Natl Acad Sci USA
  • 2008

Similar Papers

Loading similar papers…